Infinity Pharmaceuticals | INFI - Sales Revenues


Infinity Pharmaceuticals reported $583K in Sales Revenues for its fiscal quarter ending in June of 2023.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Cipla INR 65.41B 9.77B Mar/2026
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 67.33M 65.44M Dec/2025
CSL USD 8.33B 4.79B Dec/2025
Eisai JPY 219.94B 22.58B Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Grifols EUR 2B 306.7M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Infinity Pharmaceuticals USD 583K 148K Jun/2023
Ionis Pharmaceuticals USD 246M 43M Mar/2026
J&J USD 24.1B 500M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Plus Therapeutics USD 1.37M 30K Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
TG Therapeutics USD 194.8M 2.23M Mar/2026